Bionano Genomics Inc (BNGO) - Total Assets
Based on the latest financial reports, Bionano Genomics Inc (BNGO) holds total assets worth $73.58 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Bionano Genomics Inc for net asset value and shareholders' equity analysis.
Bionano Genomics Inc - Total Assets Trend (2016–2025)
This chart illustrates how Bionano Genomics Inc's total assets have evolved over time, based on quarterly financial data.
Bionano Genomics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Bionano Genomics Inc's total assets of $73.58 Million consist of 61.7% current assets and 38.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.1% |
| Accounts Receivable | $5.20 Million | 7.1% |
| Inventory | $5.45 Million | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.34 Million | 5.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Bionano Genomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BNGO company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bionano Genomics Inc's current assets represent 61.7% of total assets in 2025, a decrease from 72.6% in 2016.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 35.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 7.4% of total assets.
Bionano Genomics Inc Competitors by Total Assets
Key competitors of Bionano Genomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Bionano Genomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.98 | 1.06 | 51.65 |
| Quick Ratio | 1.74 | 0.76 | 51.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.44 Million | $2.15 Million | $363.08 Million |
Bionano Genomics Inc - Advanced Valuation Insights
This section examines the relationship between Bionano Genomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.30 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -4.0% |
| Total Assets | $73.58 Million |
| Market Capitalization | $12.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bionano Genomics Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bionano Genomics Inc's assets decreased by 4.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bionano Genomics Inc (2016–2025)
The table below shows the annual total assets of Bionano Genomics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $73.58 Million | -4.03% |
| 2024-12-31 | $76.67 Million | -64.24% |
| 2023-12-31 | $214.40 Million | -30.28% |
| 2022-12-31 | $307.50 Million | -18.46% |
| 2021-12-31 | $377.10 Million | +523.83% |
| 2020-12-31 | $60.45 Million | +100.11% |
| 2019-12-31 | $30.21 Million | +21.79% |
| 2018-12-31 | $24.80 Million | +144.48% |
| 2017-12-31 | $10.15 Million | -31.39% |
| 2016-12-31 | $14.79 Million | -- |
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It als… Read more